Galectin Therapeutics Reports no Drug-Drug Interaction

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

NORCROSS, Ga., May 14, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that in an open-label Phase 1 study with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observed. This study was required by the U.S. Food and Drug Administration (FDA) and the primary objective was to determine if single or multiple intravenous (IV) doses of GR-MD-02 affect the pharmacokinetics (PK) of midazolam. The secondary objective was to assess the safety and tolerability of GR-MD-02 when administered concomitantly with midazolam.

The lack of a drug interaction in this study will permit Galectin to expand the number of patients eligible for its Phase 2 clinical trial. In addition, should GR-MD-02 be approved for marketing, the success of this study supports a broader patient population for the drug label.

"The success of this study is important to the advancement of GR-MD-02 as a treatment for non-alcoholic steatohepatitis (NASH) with fibrosis and/or cirrhosis because midazolam is widely used in clinical practice for mild, conscious sedation. Importantly, midazolam provides a good model for many other commonly used drugs that are metabolized by the CYP 3A4 enzyme system, to which patients with liver disease might be exposed to for a variety of clinical indications," said Peter G. Traber, M.D., president, chief executive officer and chief medical officer of Galectin Therapeutics. "We are very pleased to find no pharmacokinetic issues with GR-MD-02 and midazolam following single and multiple doses of both drugs. The rigorous conduct of this study was a requirement by the FDA and overcomes one more important hurdle in our efforts to bring a drug to address the needs of a growing number of patients who develop NASH, and subsequently progress to liver fibrosis and cirrhosis. "

The open-label Phase 1 study in normal healthy volunteer subjects tested a single dose of IV midazolam in the absence of GR-MD-02, following a single IV dose of GR-MD-02 and following three weekly IV doses of GR-MD-02. The four dosing periods were spaced one week apart, with midazolam PK determined in dosing periods one, two and four. A total of 17 subjects completed the study and met the primary endpoint of midazolam clearance when administered alone, compared with when administered with single and multiple doses of GR-MD-02. Drug to drug interaction studies are an integral part of understanding how a drug will affect patients who are also on other drugs. With completion of this study, the company does not anticipate further drug-drug interaction studies will be required in the development of GR-MD-02.

Dr. Traber added, "We are preparing to begin patient screening for our Phase 2 program in the coming weeks, which consists of a study in patients with NASH cirrhosis and a study in NASH patients with advanced fibrosis, but not cirrhosis. It should be noted as we embark on the next steps of our development strategy that Galectin has significantly invested in the chemical and pharmaceutical development of our compound, has implemented analytical methods to meet FDA requirements and is continually generating the necessary data to adequately characterize our drug compound. When a new chemical entity is chosen and defined as a potential drug candidate, the drug must be fully characterized. This drug characterization is necessary to understand the behavior of the drug, in solid state (drug substance) as well as in solution (drug product). Our working relationships with academic institutions and commercial analytical organizations with expertise in carbohydrate chemistry and analytical characterization of complex carbohydrate molecules helps to assure that our products are adequately characterized using the latest available technologies."

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for GR-MD-02 will lead to the first therapy for the treatment of fatty liver disease with cirrhosis. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of its other drugs in development. The Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies. Carbohydrates are a relatively new drug class, and regulatory requirements are evolving; we cannot assure that will be able to meet such requirements in a timely and cost effective manner in the manufacturing and characterization of our products. Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

Jack Callicutt, Chief Financial Officer (678) 620-3186 LHA Kim Golodetz (212) 838-3777

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 111

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 170

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 103

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 161

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 61

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 120

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading

Top 5 Most Recently Viewed Articles

Gap Inc. Sees Minor Sales Growth Amid Market Challenges

Updated Category News Views 254

Gap Inc. Experiences Modest Growth Gap Inc. demonstrated resilience in a challenging market, achieving a 1% increase in net sales compared to the previous year. The comparable sales rose by 3%, reflecting the brand's enhancement strategies. Brand Performance Highlight Each of Gap Inc.'s four major brands—Old Navy, Gap, Banana Republic, and Athleta—gained market share,...

Continue Reading
Innovative Lock Design Enhances Security for Commercial Trailers

Updated Category News Views 761

The SMART LOC: A Game-Changer for Trucking Security In a world where cargo theft is a persistent challenge, the development of an innovative solution is essential. Enter the SMART LOC, a new locking mechanism designed specifically for commercial trailers. This invention aims to significantly enhance security for trucking professionals, ultimately providing much-needed...

Continue Reading
GXO Logistics Prepares for First Quarter Earnings Call Soon

Updated Category News Views 198

GXO Logistics Set for First Quarter Earnings Presentation GXO Logistics, Inc. (NYSE: GXO) is preparing for its first quarter earnings conference call, which is scheduled for May 8, 2025, at 8:30 a.m. Eastern Time. During this call, the company will share its financial results and key insights into its business performance. Interested participants are encouraged to join in...

Continue Reading
Legal Action Against Everus Construction Group for Investors

Updated Category News Views 132

Overview of Legal Proceedings Against Everus Construction Group Everus Construction Group, Inc. (NYSE: ECG) is currently facing significant legal challenges as a result of alleged securities law violations. The situation has prompted attention from shareholders and investors alike. The Gross Law Firm has taken the initiative to notify shareholders regarding this serious...

Continue Reading
Nxera Pharma and Cancer Research UK Collaborate to Combat Cancer

Updated Category News Views 121

Nxera Pharma Joins Forces with Cancer Research UK for Innovative Trials HTL0039732, a promising oral EP4 antagonist developed by Nxera, shows potential in tackling various types of cancer, especially when paired with leading immunotherapies. Currently, this drug is making progress through its Phase 1/2a clinical trials, highlighting its potential effectiveness across a...

Continue Reading